Global pharma giant Eli Lilly and Company says that its experimental treatment EBGLYSS has delivered strong results in a late-stage clinical trial for children suffering from moderate-to-severe atopic dermatitis, raising hopes for a new option to treat a condition that affects millions of young patients. 

The company announced positive topline data from the Phase 3 ADorable-1 trial, reporting that EBGLYSS (lebrikizumab-lbkz) met both its primary and key secondary endpoints after 16 weeks of treatment. The drug significantly reduced disease severity while helping clear skin and relieve the persistent itching that defines the chronic inflammatory skin disorder. 

Atopic dermatitis is more common in children than adults, affecting an estimated 9.6 million children in the United States, about one-third of whom live with moderate-to-severe disease. 

Following the results, Lilly said it intends to submit the data to regulators in the United States and other global markets in a bid to expand the drug’s label to include paediatric patients. 

EBGLYSS works by targeting interleukin-13 (IL-13), a key driver of the inflammatory cycle behind atopic dermatitis. By selectively blocking IL-13 signaling with high binding affinity and a slow dissociation rate, the therapy aims to interrupt the biological pathway responsible for skin barrier damage, intense itching, skin thickening, and infections. 

In the ADorable-1 study, paediatric patients were randomly assigned either a placebo or a weight-based dose of EBGLYSS. All participants used topical corticosteroids beginning two weeks before randomization and throughout the 16-week trial, though treatment could be reduced or stopped once patients achieved an Investigator’s Global Assessment score of 2 or lower. 

The trial’s co-primary endpoints were EASI-75 and IGA 0,1 at Week 16, key measures used to assess improvements in eczema severity and skin clearance. Secondary endpoints evaluated deeper disease control, including EASI-90—a greater level of symptom improvement—and significant itch relief measured by at least a four-point drop on the Pruritus Numeric Rating Scale. 

The results position EBGLYSS as a potential new therapy for children battling moderate-to-severe eczema, pending regulatory review.